Asia Pacific Blood Brain Barrier Technologies Market

Market Introduction

Asia Pacific blood brain barrier technologies market is analyzed based countries such as China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. The Asia Pacific region is expected to be the fastest-growing region among all other regions. The growth of the market in this region is expected to grow at a faster pace owing to factors such as large pool of patients, increasing awareness about neurodegenerative disorders, and advancement in technology coupled with growing R&D in developing countries in the Asia Pacific region. Additionally, developing healthcare infrastructure and increasing investments to boost the manufacturing capacities are projected to drive the Asia Pacific blood brain barrier technologies market during the forecast period.

As of September 2021, COVID-19 cases reached 56.5 million in Asia Pacific, according to the United Nations Office for the Coordination of Humanitarian Affairs (UNOCHA). COVID-19 also attacks the brain, which may result in a global or focal neurologic manifestation, according to few studies carried out in Asia. It has been reported that COVID-19 infection can also show several neurologic manifestations, such as ageusia, anosmia, or dysgeusia, and causes neurologic disorders such as stroke, encephalopathy, Guillain-Barre syndrome, and many more. Emerging evidence has revealed that SARS-CoV-2 can affect the central nervous system (CNS) in addition to the respiratory system. Scientists detected SARS-CoV-2 RNA in multiple organs, including post-mortem brain tissue of patients with COVID-19. A recent study of COVID-19 patients following an autopsy showed that SARS-CoV-2 was present in cortical neurons. In addition, the results from human brain organoids also illustrated the neuroinvasion capability of SARS-CoV-2. Together, these data provide evidence for SARS-CoV-2 infection in the human CNS, but how the virus invades the brain is still undiscovered. In few research studies, it has been observed the spike protein of the SARS-CoV-2 virus also crosses the blood brain barrier in several models. As a result, the blood-brain barrier technologies market in the region has seen significant expansion due to the COVID-19 impact.

Asia Pacific Blood Brain Barrier Technologies Strategic Insights

Strategic insights for the Asia Pacific Blood Brain Barrier Technologies provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Blood Brain Barrier Technologies Report Scope

Asia Pacific Blood Brain Barrier Technologies Regional Insights

The geographic scope of the Asia Pacific Blood Brain Barrier Technologies refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The blood brain barrier technologies market in Asia Pacific is expected to grow from US$ 221.98 million in 2021 to US$ 1,123.04 million by 2028; it is estimated to grow at a CAGR of 26.1% from 2021 to 2028. Neurological disorders such as epilepsy and seizures, Parkinson's disease, dementia, autism, Alzheimer's disease, brain tumors, and cerebral palsy, among others affect the brain and nerves of the human body. Epilepsy is a noncommunicable chronic brain disease that affects people of all ages. According to the World Health Organization (WHO), around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases in the world. Almost 80% of people with epilepsy live in low- and middle-income countries. The same source estimates that up to 70% of people with epilepsy could live seizure-free with proper diagnosis and treatment. Dementia is currently the seventh leading cause of death among all diseases and one of the leading causes of disability and addiction in older people worldwide. According to the WHO, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year. Dementia is caused by a variety of diseases and injuries that primarily or secondarily affect the brain. Alzheimer's disease is the most common form of dementia and may contribute to 60–70% of cases. Thus, the growing prevalence of neurological disorders demands advanced blood-brain barrier technologies for the treatment is expected to drive the market during the forecast period.

Key Market Segments

In terms of technology, the increasing permeability segment accounted for the largest share of the Asia Pacific blood brain barrier technologies market in 2021. In terms of application, the parkinson’s disease segment accounted for the largest share of the Asia Pacific blood brain barrier technologies market in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the blood brain barrier technologies market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer, Inc.; Johnson & Johnson Services, Inc.; and JCR Pharmaceuticals Co., Ltd. among others.

Reasons to buy report

• To understand the Asia Pacific blood brain barrier technologies market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Asia Pacific blood brain barrier technologies market
• Efficiently plan M&A and partnership deals in Asia Pacific blood brain barrier technologies market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific blood brain barrier technologies market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Asia Pacific region.

Asia Pacific Blood Brain Barrier Technologies Market Segmentation

Asia Pacific Blood Brain Barrier Technologies Market – By Technology

• Bispecific Antibody RMT Approach
• Trojan Horse Approach
• Increasing Permeability
• Passive Diffusion
• Other Non-Invasive BBB Technologies

Asia Pacific Blood Brain Barrier Technologies Market – By

Application

• Alzheimer’s Disease
• Epilepsy
• Parkinson’s Disease
• Multiple Sclerosis
• Hunter’s Syndrome
• Brain Cancer
• Others

Asia Pacific Blood Brain Barrier Technologies Market – By Country

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Asia Pacific Blood Brain Barrier Technologies Market – Companies Mentioned

• Teva Pharmaceutical Industries Ltd.                                         
• F. Hoffmann-La Roche Ltd                                                            
• Eli Lilly and Company                                                                     
• Bristol-Myers Squibb Company                                                   
• Pfizer, Inc.                                                                                       
• Johnson & Johnson Services, Inc.                                               
• JCR Pharmaceuticals Co., Ltd.